DK3003385T3 - Antistofsammensætning og buffersystem til denne - Google Patents

Antistofsammensætning og buffersystem til denne Download PDF

Info

Publication number
DK3003385T3
DK3003385T3 DK14730479.4T DK14730479T DK3003385T3 DK 3003385 T3 DK3003385 T3 DK 3003385T3 DK 14730479 T DK14730479 T DK 14730479T DK 3003385 T3 DK3003385 T3 DK 3003385T3
Authority
DK
Denmark
Prior art keywords
buffer system
antibody composition
antibody
composition
buffer
Prior art date
Application number
DK14730479.4T
Other languages
Danish (da)
English (en)
Inventor
Nicolas Steven Gee
Bianca Fusetti
Original Assignee
Innova Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innova Biosciences Ltd filed Critical Innova Biosciences Ltd
Application granted granted Critical
Publication of DK3003385T3 publication Critical patent/DK3003385T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
DK14730479.4T 2013-05-31 2014-05-30 Antistofsammensætning og buffersystem til denne DK3003385T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1309759.7A GB2516808A (en) 2013-05-31 2013-05-31 Antibody composition and buffer system therefor
PCT/EP2014/061281 WO2014191560A1 (en) 2013-05-31 2014-05-30 Antibody composition and buffer system therefor

Publications (1)

Publication Number Publication Date
DK3003385T3 true DK3003385T3 (da) 2020-01-06

Family

ID=48805557

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14730479.4T DK3003385T3 (da) 2013-05-31 2014-05-30 Antistofsammensætning og buffersystem til denne

Country Status (9)

Country Link
US (1) US11046753B2 (enExample)
EP (1) EP3003385B1 (enExample)
JP (2) JP2016530216A (enExample)
CN (1) CN105592860B (enExample)
AU (1) AU2014273034B2 (enExample)
DK (1) DK3003385T3 (enExample)
ES (1) ES2762501T3 (enExample)
GB (2) GB2516808A (enExample)
WO (1) WO2014191560A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65120B1 (sr) * 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111896752A (zh) * 2020-08-11 2020-11-06 上海捷门生物技术有限公司 一种适用于多种poct类仪器的c-反应蛋白试剂盒
CN113671188A (zh) * 2021-08-10 2021-11-19 江南大学 一种检测贝类食品中河豚毒素的时间分辨免疫定量试纸条
EP4218562A1 (en) 2022-01-28 2023-08-02 Charité - Universitätsmedizin Berlin Real-time breath antigen detection system and method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516873A1 (en) 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
DK0988861T3 (da) * 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
ES2407468T3 (es) * 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
CA2618068C (en) 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8492129B2 (en) * 2005-12-12 2013-07-23 Innova Biosciences, Ltd. Production of conjugates
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP2129401B8 (en) * 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
DK2318838T3 (da) 2008-07-16 2013-10-14 Radiometer Medical Aps Fast fase med høj kapacitet
JP2011241206A (ja) 2010-04-23 2011-12-01 Arkray Inc 標識抗体の安定化方法
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
US8877892B2 (en) * 2011-03-15 2014-11-04 Innova Biosciences Limited Conjugation reactions
HRP20180028T4 (hr) 2011-03-16 2020-10-02 F. Hoffmann - La Roche Ag Kromatografija izmjene iona s poboljšanom selektivnošću za odvajanje polipeptidnih monomera, agregata i fragmenata modulacijom pokretne faze
KR20120128440A (ko) 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법

Also Published As

Publication number Publication date
CN105592860A (zh) 2016-05-18
US11046753B2 (en) 2021-06-29
US20160122416A1 (en) 2016-05-05
CN105592860B (zh) 2021-02-02
JP2016530216A (ja) 2016-09-29
GB2516808A (en) 2015-02-11
WO2014191560A1 (en) 2014-12-04
ES2762501T3 (es) 2020-05-25
JP2020007343A (ja) 2020-01-16
AU2014273034B2 (en) 2019-11-21
GB2530217A (en) 2016-03-16
GB201522774D0 (en) 2016-02-03
EP3003385B1 (en) 2019-09-18
GB201309759D0 (en) 2013-07-17
ES2762501T8 (es) 2020-06-18
EP3003385A1 (en) 2016-04-13
AU2014273034A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
IL290972A (en) Anti-vista antibodies and fragments
IL289821B (en) Compositions and methods for immunotherapy
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3683235T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3026062T3 (da) Anti-pd-1-antistof og anvendelse deraf
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3292150T3 (da) Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf
HUE055044T2 (hu) MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
IL285527A (en) Compositions and methods for immunotherapy
DK3083689T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK2996556T3 (da) System til billedstyret procedure
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3300745T3 (da) Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
HUE051357T2 (hu) IL-23 kötõ antitestek